 |
|
|
|
Media Center Overview
|
|
|
Talecris Plasma Resources Supplements Its Collection: Acquisition Adds New Centers
Deal Includes Three Centers Currently Open in Las Vegas, Nevada; Montgomery, Alabama; and Rockford, Illinois with Plans to Open Up to 10 Additional Centers
RESEARCH TRIANGLE PARK, N.C. (June 12, 2007) – Talecris Biotherapeutics, Inc. announced today that its wholly owned subsidiary, Talecris Plasma Resources (http://www.talecrisplasma.com), has entered into a deal with International BioResources, LLC (IBR) to purchase three plasma collection centers and open up to 10 additional centers to further supply Talecris Biotherapeutics. The three centers purchased by Talecris are located in Las Vegas, Nevada; Montgomery, Alabama; and Rockford, Illinois. Of these centers, the Las Vegas center is licensed and the other two are operating and awaiting FDA approval for licensure. Additionally, under the terms of the agreement IBR will be responsible for building up to 10 new centers to Talecris’ specifications; Talecris Plasma Resources will have the option to purchase each of the centers opened. Financial terms of the deal were not disclosed.
The plasma donated at Talecris Plasma Resources provides the source material for the production of Talecris Biotherapeutics’ critical care protein therapies, used in the treatment of life-threatening disorders in a variety of therapeutic areas, including immunology, pulmonology, and hemostasis. In November of 2006, Talecris acquired 58 plasma centers from IBR and launched Talecris Plasma Resources in an effort to further ensure the reliable supply and safety of its products.
“To meet the growing demand for critical care protein therapies, we have been implementing an aggressive expansion plan for Talecris Plasma Resources,” said Alberto Martinez, M.D., President and CEO of Talecris Biotherapeutics. “Since January 2007, we have opened eight plasma collection centers and have several more openings scheduled this year. This aggressive schedule combined with this most recent acquisition will advance our goal of ensuring the reliability of our products from the arms of plasma donors to the arms of patients.”
Contact:
Lacy McMahon, Talecris Biotherapeutics
Tel.: 919.316.6316, Fax: 919.316.6673
E-mail: lacy.mcmahon@talecris.com
About Talecris Biotherapeutics: Inspiration. Dedication. Innovation.
Talecris Biotherapeutics is a global biotherapeutic and biotechnology company that discovers, develops and produces critical care treatments for people with life-threatening disorders in a variety of therapeutic areas including immunology, pulmonology, and hemostasis. Talecris is proudly building upon a 60-year legacy of innovation and a commitment to improving the lives of people who rely on its therapeutic products. With an emphasis on scientific inquiry and technological excellence, Talecris is expanding its current portfolio of products, programs, and services through its own world-class product development organization as well as through strategic initiatives that leverage its strengths with those of its partners.
Talecris, with revenues of approximately $1.2 billion in 2007, is headquartered in biotech hub Research Triangle Park, N.C., and employs more than 4,000 talented people worldwide.
To learn more about Talecris and how our employees are making a difference in the lives of patients and the healthcare community, visit www.talecris.com.
|
|
|
|
|
|
|
|
